Combined blood markers correctly detect early pancreatic cancer in human cancer cells
A newly identified biomarker panel could pave the way to earlier detection and better treatment for pancreatic cancer, according to new research from the Perelman School of Medicine at University of Pennsylvania. Currently over 53,000 people in the United States are diagnosed with pancreatic cancer — the fourth leading cause of cancer death — every year. The blood biomarkers, detailed today in Science Translational Medicine, correctly detected pancreatic cancer in blood samples from patients at different stages of their disease.
The majority of pancreatic cancer patients are not diagnosed until an advanced stage, beyond the point at which their tumors can be surgically removed.
A team led by Ken Zaret, PhD, director of the Penn Institute for Regenerative Medicine and the Joseph Leidy Professor of Cell and Developmental Biology, and Gloria Petersen, PhD, from the Mayo Clinic, identified a pair of biomarkers that physicians could soon use to discover the disease earlier.
“Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,” Zaret said. The authors anticipate that health care providers will use the early-detection biomarkers to test for their presence and levels in blood from pancreatic cancer patients and blood drawn from individuals with a high risk of developing pancreatic cancer, including those who have a first-degree relative with pancreatic cancer, are genetically predisposed to the disease, or who had a sudden onset of diabetes after the age of 50.
“Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer. A long standing concern has been that patients with pancreatic cancer are often not diagnosed until it is too late for the best chance at effective treatment,” said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center (ACC) at the University of Pennsylvania. “Having a biomarker test for this disease could dramatically alter the outlook for these patients.”
Novel method for discovering pancreatic cancer biomarkers
Credit: The lab of Ken Zaret, Perelman School of Medicine, University of Pennsylvania
The biomarker panel, enabled by discovery work of first author Jungsun Kim, PhD, a postdoctoral fellow in Zaret’s lab, builds on a first-of-its-kind human-cell model of pancreatic cancer progression the lab described in 2013. They used stem-cell technology to create a cell line from a patient with advanced pancreatic ductal adenocarcinoma. Genetically reprogramming late-stage human cancer cells to a stem-cell state enabled them to force the reprogrammed cells to progress to an early cancerous state, revealing secreted blood biomarkers of early-stage disease along the way.
The best candidate biomarker, plasma thrombospondin-2 (THBS2), was screened against 746 cancer and control plasma samples using an inexpensive, commercially available protein-detection assay. The team found that blood levels of THBS2, combined with levels of a known later-stage biomarker called CA19-9, was reliable at detecting the presence of pancreatic cancer in patients.
The team refined the assay with independent investigations of plasma samples from patients with different stages of cancer, from individuals with benign pancreatic disease, and from healthy controls, all obtained from Petersen, who directs the biospecimen resource program for pancreas research at the Mayo Clinic.
“Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer,” Zaret said. “Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method.” The combination panel also improved the ability to distinguish cases of cancer from pancreatitis. The panel will next be validated in a set of samples from pancreatic cancer patients who provided a research blood sample prior to their diagnosis.
The Latest on: Pancreatic cancer
- PurpleStride Walk to End Pancreatic Cancer on September 16, 2017 at 12:24 pm
SAN DIEGO (NEWS 8) - Hundreds of runners and walkers donning purple gear packed De Anza Cove on Saturday morning for the annual PurpleStride Walk to End Pancreatic Cancer. Saturday's event was emceed by KFMB Stations' own Miles Himmel, son of beloved News ... […]
- Middle-East and Africa Pancreatic Cancer Therapeutics Market growing at a CAGR of 6.865 % on September 16, 2017 at 2:21 am
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning ... […]
- Annual Paramus pancreatic cancer walk raises funds for early detection on September 14, 2017 at 9:04 pm
This weekend, thousands of strangers will come together for a common goal: to help raise funds for research on pancreatic cancer, a disease considered one of the deadliest of cancers because of how hard it is to detect. The mix of relatives, survivors ... […]
- PurpleRideStride MN to create pancreatic cancer awareness on September 14, 2017 at 1:59 pm
GOLDEN VALLEY, Minn. - Experts say pancreatic cancer is the world’s toughest cancer, with a five year survival of just 9 percent in the United States. Of the approximate 980 Minnesotans diagnosed with the disease this year, only 88 will live to see the ... […]
- Global Pancreatic Cancer Partnering 2010 to 2017 on September 14, 2017 at 9:04 am
The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies. The report provides an analysis of partnering deals. The majority of deals are discovery or development stage ... […]
- New app could spot pancreatic cancer on September 13, 2017 at 10:52 pm
BiliScreen is a new app developed by researchers at the University of Washington, that the creators claim can screen for pancreatic cancer and other diseases simply by taking a selfie on a smartphone. Select any pre-existing folders to add the current post to. […]
- Trial compares laparoscopic and open surgeries for pancreatic cancer on September 13, 2017 at 10:38 am
A randomized clinical trial has compared key-hole (laparoscopic) surgery and open surgery in pancreatic cancer patients undergoing pancreaticoduodenectomy, or the Whipple procedure. The procedure is used to treat tumors located in the head of the pancreas ... […]
- A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It on September 11, 2017 at 3:52 am
A new type of cancer medication, called PARP inhibitors, is gaining traction in clinical practice. Already the FDA has approved several drugs in this class: Lynparza (olaparib, AstraZeneca), Rubraca (rucaparib, Clovis), and Zejula (niraparib, Tesaro). […]
- ERYTECH Announces Positive Full Results from Phase 2b Study of Eryaspase in Combination with Chemotherapy for Treatment of Metastatic Pancreatic Cancer in Second-Line on September 7, 2017 at 10:35 pm
LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells ... […]
- Find Out Current Status of Pancreatic Cancer Market to 2021 on September 7, 2017 at 6:34 am
Research N Reports statistical surveying authorities lead a triangulated approach of essential and auxiliary research procedures and carry out a complete examination of various components, including mechanical progressions and the demand-supply drifts in ... […]
via Google News and Bing News